StoxKrishna Institute of Medical Sciences vs Rubicon Research: share price & financials comparison
NSE: KIMS vs RUBICON · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Krishna Institute of Medical Sciences vs Rubicon Research at a glance
Krishna Institute of Medical Sciences (KIMS) has a market capitalisation of ₹30,366 Cr, against ₹27,466 Cr for Rubicon Research (RUBICON). Over the past year Rubicon Research has returned +176.3%, compared with -1.7% for Krishna Institute of Medical Sciences. On valuation, Rubicon Research trades at a lower P/E of 84.6 versus 143.0. Rubicon Research earns a higher return on equity (22.9% vs 5.4%). Krishna Institute of Medical Sciences comes out ahead on valuation. Rubicon Research comes out ahead on size, profitability, financial health, momentum and technicals. Across the scored metrics below, Krishna Institute of Medical Sciences leads on 3 and Rubicon Research on 11. On StoxGud's 10-point checklist, Krishna Institute of Medical Sciences scores 4/10 and Rubicon Research scores 8/10.
| Metric | Krishna Institute of Medical Sciences | Rubicon Research |
|---|---|---|
| Size | ||
| Market cap | ₹30,366 Cr | ₹27,466 Cr |
| Revenue (latest FY) | ₹3,905 Cr | ₹1,754 Cr |
| Net profit (latest FY) | ₹241 Cr | ₹247 Cr |
| Valuation | ||
| P/E | 143.0 | 84.6 |
| P/B | 7.72 | 19.39 |
| Dividend yield | 0.68% | 0.00% |
| Profitability | ||
| Return on equity | 5.4% | 22.9% |
| Net profit margin | 4.6% | 15.5% |
| Operating margin | 19.3% | 23.8% |
| Growth | ||
| Revenue growth (YoY) | +39.9% | +39.9% |
| Net profit growth (YoY) | +11.8% | +68.0% |
| Revenue CAGR (multi-year) | +24.0% | — |
| Financial health | ||
| Debt to equity | 0.90 | 0.28 |
| Momentum | ||
| 1-month return | +4.2% | +5.3% |
| 1-year return | -1.7% | +176.3% |
| 3-year CAGR | +24.8% | — |
| 5-year CAGR | +25.3% | — |
| Distance from 52W high | -15.0% | -10.8% |
| Technicals | ||
| RSI (14) | 66 | 65 |
| Price vs 200-day avg | -0.7% | +35.2% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Krishna Institute of Medical Sciences | Rubicon Research |
|---|---|---|
| Price above 50-day average | ✗ | ✗ |
| Price above 200-day average | ✗ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✓ |
| Positive 1-year return | ✗ | ✓ |
| Return on equity above 15% | ✗ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✗ | ✗ |
| Score | 4/10 | 8/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Krishna Institute of Medical Sciences or Rubicon Research?
Krishna Institute of Medical Sciences has a market cap of ₹30,366 Cr and Rubicon Research has a market cap of ₹27,466 Cr as of 06 Nov 2026.
Which has a lower P/E, Krishna Institute of Medical Sciences or Rubicon Research?
Rubicon Research has the lower P/E: Krishna Institute of Medical Sciences trades at 143.0 and Rubicon Research at 84.6.
Which gave better returns in the last year, Krishna Institute of Medical Sciences or Rubicon Research?
Rubicon Research did better: Krishna Institute of Medical Sciences returned -1.7% and Rubicon Research returned +176.3% over one year.
Is Krishna Institute of Medical Sciences or Rubicon Research a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Krishna Institute of Medical Sciences scores 4/10 and Rubicon Research scores 8/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.